Groot-Loonen J J, Pinkerton C R, Morris-Jones P H, Pritchard J
Royal Marsden Hospital, Sutton, Surrey.
Arch Dis Child. 1990 Sep;65(9):968-70. doi: 10.1136/adc.65.9.968.
Three hundred and eighty one children with Wilms' tumour were treated on the United Kingdom Children's Cancer Study Group WT1 Study (1980/6). Seventy one patients relapsed during or after treatment, which included surgery and chemotherapy, with irradiation depending on stage and histology. Despite treatment with various combinations of chemotherapy, surgery, and radiotherapy there were only 17 survivors. For unfavourable histology, any stage, only two of 20 survive. We conclude that, after relapse, even for patients who have had localised disease and favourable histology, the 'salvage' rate is little more than 50% and for all others the likelihood of cure is very small. Three of 41 children who relapsed less than 12 months from diagnosis survive, compared with 14 of 30 who relapsed later. It is essential that even with this 'good prognosis' tumour initial treatment is optimal and given by centres experienced in management of children's cancer. Furthermore, there is a clear need for additional effective chemotherapeutic agents for relapsed patients.
381名患有肾母细胞瘤的儿童参加了英国儿童癌症研究小组的WT1研究(1980/6)。71名患者在治疗期间或治疗后复发,治疗包括手术和化疗,放疗则根据分期和组织学情况进行。尽管采用了化疗、手术和放疗的各种联合治疗,但仅有17名幸存者。对于任何分期的不良组织学类型,20名患者中只有2名存活。我们得出结论,复发后,即使对于患有局限性疾病且组织学类型良好的患者,“挽救”率也仅略高于50%,而对于其他所有患者,治愈的可能性非常小。诊断后12个月内复发的41名儿童中有3名存活,而诊断12个月后复发的30名儿童中有14名存活。至关重要的是,即使对于这种“预后良好”的肿瘤,初始治疗也应达到最佳,并由在儿童癌症管理方面经验丰富的中心进行。此外,对于复发患者,显然需要更多有效的化疗药物。